25 XP 0   0   10  
0coffee
Main menu
3rd party ad coffee SUPPORTERis ad-free.

Navidea Biopharmaceuticals Inc
Buy, Hold or Sell?

Let's analyze Navidea together

I guess you are interested in Navidea Biopharmaceuticals Inc. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Navidea Biopharmaceuticals Inc. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

Get notifications about Navidea Biopharmaceuticals Inc

I send you an email if I find something interesting about Navidea Biopharmaceuticals Inc.

1. Quick Overview

1.1. Quick analysis of Navidea (30 sec.)










1.2. What can you expect buying and holding a share of Navidea? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
10.0%

What is your share worth?

Current worth
$-0.08
Expected worth in 1 year
$-0.43
How sure are you?
20.0%

+ What do you gain per year?

Total Gains per Share
$-0.35
Return On Investment
-350,427.8%

For what price can you sell your share?

Current Price per Share
$0.00
Expected price per share
$0.0001 - $0.001
How sure are you?
50%
3rd party ad coffee SUPPORTERis ad-free.

2. Detailed Analysis

2.1. Valuation of Navidea (5 min.)




Live pricePrice per Share (EOD)
$0.00
Intrinsic Value Per Share
$-2.35 - $0.19
Total Value Per Share
$-2.43 - $0.11

2.2. Growth of Navidea (5 min.)




Is Navidea growing?

Current yearPrevious yearGrowGrow %
How rich?-$8.1m$624.7k-$8.7m-107.7%

How much money is Navidea making?

Current yearPrevious yearGrowGrow %
Making money-$17.2m-$11.7m-$5.4m-31.9%
Net Profit Margin-26,221.7%-2,207.1%--

How much money comes from the company's main activities?

2.3. Financial Health of Navidea (5 min.)




2.4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  

3rd party ad coffee SUPPORTERis ad-free.

3. Summary and Key Metrics

3.1. What can you expect buying and holding a share of Navidea?

Welcome investor! Navidea's management wants to use your money to grow the business. In return you get a share of Navidea.

First you should know what it really means to hold a share of Navidea. And how you can make/lose money.

Speculation

The Price per Share of Navidea is $0.0001. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Navidea.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Navidea, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $-0.08. Based on the TTM, the Book Value Change Per Share is $-0.09 per quarter. Based on the YOY, the Book Value Change Per Share is $-0.01 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Navidea.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps-0.17-172,005.9%-0.17-172,005.9%-0.12-117,210.9%-0.13-134,674.2%-0.11-112,696.1%
Usd Book Value Change Per Share-0.09-87,606.9%-0.09-87,606.9%-0.01-14,209.7%-0.04-40,349.4%-0.01-6,732.3%
Usd Dividend Per Share0.000.0%0.000.0%0.00173.5%0.0034.7%0.0017.3%
Usd Total Gains Per Share-0.09-87,606.9%-0.09-87,606.9%-0.01-14,036.2%-0.04-40,314.7%-0.01-6,714.9%
Usd Price Per Share0.21-0.21-1.00-0.94-1.10-
Price to Earnings Ratio-1.22--1.22--8.53--8.16--5.98-
Price-to-Total Gains Ratio-2.40--2.40--71.24--7.93--13.63-
Price to Book Ratio-2.58--2.58-160.20-24.78-6.54-
Price-to-Total Gains Ratio-2.40--2.40--71.24--7.93--13.63-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share0.0001
Number of shares10000000
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share-0.09-0.04
Usd Total Gains Per Share-0.09-0.04
Gains per Quarter (10000000 shares)-876,069.40-403,146.96
Gains per Year (10000000 shares)-3,504,277.61-1,612,587.83
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10-3504278-35042881388-1613975-1612598
20-7008555-70085662775-3227951-3225186
30-10512833-105128444163-4841926-4837774
40-14017110-140171225551-6455902-6450362
50-17521388-175214006938-8069877-8062950
60-21025666-210256788326-9683853-9675538
70-24529943-245299569713-11297828-11288126
80-28034221-2803423411101-12911804-12900714
90-31538498-3153851212489-14525779-14513302
100-35042776-3504279013876-16139755-16125890

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.01.00.00.0%0.03.00.00.0%0.05.00.00.0%1.09.00.010.0%4.027.00.012.9%
Book Value Change Per Share0.01.00.00.0%1.02.00.033.3%1.04.00.020.0%2.08.00.020.0%12.018.01.038.7%
Dividend per Share0.00.01.00.0%1.00.02.033.3%1.00.04.020.0%1.00.09.010.0%4.00.027.012.9%
Total Gains per Share0.01.00.00.0%1.02.00.033.3%1.04.00.020.0%2.08.00.020.0%12.018.01.038.7%
3rd party ad coffee SUPPORTERis ad-free.

3.2. Key Performance Indicators

The key performance indicators of Navidea Biopharmaceuticals Inc compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---0.088-0.0880%-0.014-84%-0.040-54%-0.007-92%
Book Value Per Share---0.081-0.0810%0.006-1403%-0.008-90%-0.147+81%
Current Ratio--0.3220.3220%1.016-68%0.992-68%1.311-75%
Debt To Asset Ratio--2.8632.8630%0.906+216%1.275+125%2.242+28%
Debt To Equity Ratio----0%-0%1.401-100%0.777-100%
Dividend Per Share----0%0.000-100%0.000-100%0.000-100%
Enterprise Value--10498584.00010498584.0000%98294775.000-89%90599431.360-88%89013044.980-88%
Eps---0.172-0.1720%-0.117-32%-0.135-22%-0.113-34%
Ev To Ebitda Ratio---0.752-0.7520%-8.542+1035%-8.462+1025%-5.755+665%
Ev To Sales Ratio--159.913159.9130%184.934-14%1039.087-85%541.522-70%
Free Cash Flow Per Share---0.094-0.0940%-0.105+12%-0.067-28%-0.057-39%
Free Cash Flow To Equity Per Share---0.022-0.0220%0.016-243%-0.005-76%-0.007-69%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%1.0000%
Intrinsic Value_10Y_max--0.192--------
Intrinsic Value_10Y_min---2.350--------
Intrinsic Value_1Y_max---0.041--------
Intrinsic Value_1Y_min---0.132--------
Intrinsic Value_3Y_max---0.077--------
Intrinsic Value_3Y_min---0.488--------
Intrinsic Value_5Y_max---0.058--------
Intrinsic Value_5Y_min---0.943--------
Market Cap10008.400-209900%21017640.00021017640.0000%100084000.000-79%94533341.360-78%110179473.080-81%
Net Profit Margin---262.217-262.2170%-22.071-92%-151.425-42%-76.192-71%
Operating Margin---214.021-214.0210%-22.023-90%-135.458-37%-72.282-66%
Operating Ratio--215.021215.0210%24.065+794%139.854+54%75.184+186%
Pb Ratio-0.001+100%-2.581-2.5810%160.200-102%24.778-110%6.544-139%
Pe Ratio-0.001+100%-1.221-1.2210%-8.532+599%-8.162+569%-5.976+389%
Price Per Share0.000-209900%0.2100.2100%1.000-79%0.945-78%1.101-81%
Price To Free Cash Flow Ratio-0.001+100%-2.241-2.2410%-9.489+323%-9.551+326%-4.801+114%
Price To Total Gains Ratio-0.001+100%-2.397-2.3970%-71.244+2872%-7.934+231%-13.626+468%
Quick Ratio--0.2010.2010%0.816-75%0.847-76%1.162-83%
Return On Assets---3.938-3.9380%-1.765-55%-2.403-39%-1.545-61%
Return On Equity----0%-0%-3.4820%-1.0830%
Total Gains Per Share---0.088-0.0880%-0.014-84%-0.040-54%-0.007-92%
Usd Book Value---8143310.000-8143310.0000%624743.000-1403%-790937.800-90%-14722132.500+81%
Usd Book Value Change Per Share---0.088-0.0880%-0.014-84%-0.040-54%-0.007-92%
Usd Book Value Per Share---0.081-0.0810%0.006-1403%-0.008-90%-0.147+81%
Usd Dividend Per Share----0%0.000-100%0.000-100%0.000-100%
Usd Enterprise Value--10498584.00010498584.0000%98294775.000-89%90599431.360-88%89013044.980-88%
Usd Eps---0.172-0.1720%-0.117-32%-0.135-22%-0.113-34%
Usd Free Cash Flow---9376919.000-9376919.0000%-10547579.000+12%-6738868.600-28%-5745444.000-39%
Usd Free Cash Flow Per Share---0.094-0.0940%-0.105+12%-0.067-28%-0.057-39%
Usd Free Cash Flow To Equity Per Share---0.022-0.0220%0.016-243%-0.005-76%-0.007-69%
Usd Market Cap10008.400-209900%21017640.00021017640.0000%100084000.000-79%94533341.360-78%110179473.080-81%
Usd Price Per Share0.000-209900%0.2100.2100%1.000-79%0.945-78%1.101-81%
Usd Profit---17215039.000-17215039.0000%-11730931.000-32%-13331582.200-23%-11200903.500-35%
Usd Revenue--65652.00065652.0000%531513.000-88%372263.400-82%4629624.600-99%
Usd Total Gains Per Share---0.088-0.0880%-0.014-84%-0.040-54%-0.007-92%
 EOD+2 -6MRQTTM+0 -0YOY+7 -305Y+5 -3310Y+8 -30

3.3 Fundamental Score

Let's check the fundamental score of Navidea Biopharmaceuticals Inc based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-0.001
Price to Book Ratio (EOD)Between0-1-0.001
Net Profit Margin (MRQ)Greater than0-262.217
Operating Margin (MRQ)Greater than0-214.021
Quick Ratio (MRQ)Greater than10.201
Current Ratio (MRQ)Greater than10.322
Debt to Asset Ratio (MRQ)Less than12.863
Debt to Equity Ratio (MRQ)Less than10.000
Return on Equity (MRQ)Greater than0.150.000
Return on Assets (MRQ)Greater than0.05-3.938
Total1/10 (10.0%)

3.4 Technical Score

Let's check the technical score of Navidea Biopharmaceuticals Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5027.880
Ma 20Greater thanMa 500.001
Ma 50Greater thanMa 1000.001
Ma 100Greater thanMa 2000.001
OpenGreater thanClose0.000
Total0/5 (0.0%)

4. In-depth Analysis

4.1 About Navidea Biopharmaceuticals Inc

Navidea Biopharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. It operates in two segments, Diagnostic Substances and Therapeutic Development Programs. The company develops Manocept platform to target the CD206 mannose receptor expressed on activated macrophages for a range of diagnostic modalities, including single photon emission computed tomography, positron emission tomography (PET), gamma-scanning, and intra-operative and/or optical-fluorescence detection, as well as delivery of therapeutic compounds that target macrophages, and immune-and inflammation-involved diseases. It develops NAV3-31, which has completed Phase IIb clinical trials for evaluating imaging repeatability, reproducibility, and stability, as well as the capacity of Tc99m tilmanocept imaging for treatment of anti-tumor necrosis factor alpha therapy in patients with moderate to severe rheumatoid arthritis (RA); NAV3-35 that is in a Phase IIb clinical trial for RA imaging; NAV3-33, which is in Phase III clinical trial for RA; and NAV3-32, which is Phase 2b trial for RA-involved joints. The company is also developing Tc99m tilmanocept for cardiovascular, kaposi's sarcoma, tuberculosis, and other immunotherapeutic applications. The company was formerly known as Neoprobe Corporation and changed its name to Navidea Biopharmaceuticals, Inc. in January 2012. Navidea Biopharmaceuticals, Inc. was incorporated in 1983 and is headquartered in Dublin, Ohio.

Fundamental data was last updated by Penke on 2024-12-06 13:47:03.

4.2 In-depth Summary

4.2.1. Financial Health Summary

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is unable to pay all its short-term debts.
The company is just not able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is unable to pay all its debts by selling its assets.

4.2.2. Valuation Summary

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is expensive.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.
3rd party ad coffee SUPPORTERis ad-free.

4.3 Financial Health

4.3.1. Profitability

4.3.1 Profitability
4.3.1.1. Net Profit Margin

Measures how much net profit Navidea earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Navidea to the Biotechnology industry mean.
  • A Net Profit Margin of -26,221.7% means that $-262.22 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Navidea Biopharmaceuticals Inc:

  • The MRQ is -26,221.7%. The company is making a huge loss. -2
  • The TTM is -26,221.7%. The company is making a huge loss. -2
Trends
Current periodCompared to+/- 
MRQ-26,221.7%TTM-26,221.7%0.0%
TTM-26,221.7%YOY-2,207.1%-24,014.6%
TTM-26,221.7%5Y-15,142.5%-11,079.1%
5Y-15,142.5%10Y-7,619.2%-7,523.3%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-26,221.7%-109.4%-26,112.3%
TTM-26,221.7%-221.4%-26,000.3%
YOY-2,207.1%-208.7%-1,998.4%
5Y-15,142.5%-346.2%-14,796.3%
10Y-7,619.2%-470.4%-7,148.8%
4.3.1.2. Return on Assets

Shows how efficient Navidea is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Navidea to the Biotechnology industry mean.
  • -393.8% Return on Assets means that Navidea generated $-3.94 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Navidea Biopharmaceuticals Inc:

  • The MRQ is -393.8%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -393.8%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-393.8%TTM-393.8%0.0%
TTM-393.8%YOY-176.5%-217.2%
TTM-393.8%5Y-240.3%-153.5%
5Y-240.3%10Y-154.5%-85.7%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-393.8%-11.6%-382.2%
TTM-393.8%-12.0%-381.8%
YOY-176.5%-11.2%-165.3%
5Y-240.3%-12.6%-227.7%
10Y-154.5%-14.1%-140.4%
4.3.1.3. Return on Equity

Shows how efficient Navidea is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Navidea to the Biotechnology industry mean.
  • 0.0% Return on Equity means Navidea generated $0.00 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Navidea Biopharmaceuticals Inc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-0.0%
TTM-5Y-348.2%+348.2%
5Y-348.2%10Y-108.3%-240.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--14.6%+14.6%
TTM--16.1%+16.1%
YOY--14.6%+14.6%
5Y-348.2%-18.5%-329.7%
10Y-108.3%-19.3%-89.0%
3rd party ad coffee SUPPORTERis ad-free.

4.3.2. Operating Efficiency of Navidea Biopharmaceuticals Inc.

4.3.2. Operating Efficiency
4.3.2.1. Operating Margin

Measures how efficient Navidea is operating .

  • Measures how much profit Navidea makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Navidea to the Biotechnology industry mean.
  • An Operating Margin of -21,402.1% means the company generated $-214.02  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Navidea Biopharmaceuticals Inc:

  • The MRQ is -21,402.1%. The company is operating very inefficient. -2
  • The TTM is -21,402.1%. The company is operating very inefficient. -2
Trends
Current periodCompared to+/- 
MRQ-21,402.1%TTM-21,402.1%0.0%
TTM-21,402.1%YOY-2,202.3%-19,199.8%
TTM-21,402.1%5Y-13,545.8%-7,856.3%
5Y-13,545.8%10Y-7,228.2%-6,317.5%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-21,402.1%-204.6%-21,197.5%
TTM-21,402.1%-316.3%-21,085.8%
YOY-2,202.3%-216.5%-1,985.8%
5Y-13,545.8%-378.6%-13,167.2%
10Y-7,228.2%-480.3%-6,747.9%
4.3.2.2. Operating Ratio

Measures how efficient Navidea is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 215.02 means that the operating costs are $215.02 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Navidea Biopharmaceuticals Inc:

  • The MRQ is 215.021. The company is inefficient in keeping operating costs low. -1
  • The TTM is 215.021. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ215.021TTM215.0210.000
TTM215.021YOY24.065+190.956
TTM215.0215Y139.854+75.167
5Y139.85410Y75.184+64.670
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ215.0212.284+212.737
TTM215.0213.198+211.823
YOY24.0653.263+20.802
5Y139.8544.651+135.203
10Y75.1846.419+68.765
3rd party ad coffee SUPPORTERis ad-free.

4.4.3. Liquidity of Navidea Biopharmaceuticals Inc.

4.4.3. Liquidity
4.4.3.1. Current Ratio

Measures if Navidea is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 0.32 means the company has $0.32 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Navidea Biopharmaceuticals Inc:

  • The MRQ is 0.322. The company is unable to pay all its short-term debts. -2
  • The TTM is 0.322. The company is unable to pay all its short-term debts. -2
Trends
Current periodCompared to+/- 
MRQ0.322TTM0.3220.000
TTM0.322YOY1.016-0.693
TTM0.3225Y0.992-0.669
5Y0.99210Y1.311-0.320
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.3223.596-3.274
TTM0.3223.869-3.547
YOY1.0164.644-3.628
5Y0.9925.971-4.979
10Y1.3116.240-4.929
4.4.3.2. Quick Ratio

Measures if Navidea is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Navidea to the Biotechnology industry mean.
  • A Quick Ratio of 0.20 means the company can pay off $0.20 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Navidea Biopharmaceuticals Inc:

  • The MRQ is 0.201. The company is just not able to pay all its short-term debts with the most liquid assets. -1
  • The TTM is 0.201. The company is just not able to pay all its short-term debts with the most liquid assets. -1
Trends
Current periodCompared to+/- 
MRQ0.201TTM0.2010.000
TTM0.201YOY0.816-0.615
TTM0.2015Y0.847-0.646
5Y0.84710Y1.162-0.315
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.2013.090-2.889
TTM0.2013.413-3.212
YOY0.8164.349-3.533
5Y0.8475.953-5.106
10Y1.1626.435-5.273
3rd party ad coffee SUPPORTERis ad-free.

4.5.4. Solvency of Navidea Biopharmaceuticals Inc.

4.5.4. Solvency
4.5.4.1. Debt to Asset Ratio

Measures how much % of Navidea assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Navidea to Biotechnology industry mean.
  • A Debt to Asset Ratio of 2.86 means that Navidea assets are financed with 286.3% credit (debt) and the remaining percentage (100% - 286.3%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Navidea Biopharmaceuticals Inc:

  • The MRQ is 2.863. The company is unable to pay all its debts by selling its assets. -2
  • The TTM is 2.863. The company is unable to pay all its debts by selling its assets. -2
Trends
Current periodCompared to+/- 
MRQ2.863TTM2.8630.000
TTM2.863YOY0.906+1.957
TTM2.8635Y1.275+1.588
5Y1.27510Y2.242-0.967
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ2.8630.346+2.517
TTM2.8630.347+2.516
YOY0.9060.313+0.593
5Y1.2750.365+0.910
10Y2.2420.383+1.859
4.5.4.2. Debt to Equity Ratio

Measures if Navidea is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Navidea to the Biotechnology industry mean.
  • A Debt to Equity ratio of 0.0% means that company has $0.00 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Navidea Biopharmaceuticals Inc:

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.000
TTM-YOY-0.000
TTM-5Y1.401-1.401
5Y1.40110Y0.777+0.624
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-0.393-0.393
TTM-0.432-0.432
YOY-0.385-0.385
5Y1.4010.455+0.946
10Y0.7770.498+0.279
3rd party ad coffee SUPPORTERis ad-free.

4.6. Market Valuation

4.6.1. Earnings Per Share
4.6.2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Navidea generates.

  • Above 15 is considered overpriced but always compare Navidea to the Biotechnology industry mean.
  • A PE ratio of -1.22 means the investor is paying $-1.22 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Navidea Biopharmaceuticals Inc:

  • The EOD is -0.001. Based on the earnings, the company is expensive. -2
  • The MRQ is -1.221. Based on the earnings, the company is expensive. -2
  • The TTM is -1.221. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-0.001MRQ-1.221+1.220
MRQ-1.221TTM-1.2210.000
TTM-1.221YOY-8.532+7.311
TTM-1.2215Y-8.162+6.941
5Y-8.16210Y-5.976-2.186
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-0.001-2.323+2.322
MRQ-1.221-2.493+1.272
TTM-1.221-3.148+1.927
YOY-8.532-3.251-5.281
5Y-8.162-5.992-2.170
10Y-5.976-6.690+0.714
4.6.2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Navidea Biopharmaceuticals Inc:

  • The EOD is -0.001. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -2.241. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -2.241. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-0.001MRQ-2.241+2.240
MRQ-2.241TTM-2.2410.000
TTM-2.241YOY-9.489+7.247
TTM-2.2415Y-9.551+7.310
5Y-9.55110Y-4.801-4.750
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-0.001-3.079+3.078
MRQ-2.241-3.295+1.054
TTM-2.241-3.671+1.430
YOY-9.489-4.475-5.014
5Y-9.551-8.015-1.536
10Y-4.801-9.197+4.396
3rd party ad coffee SUPPORTERis ad-free.
4.6.2. Book Value per Share
4.6.2.1. Price to Book Ratio

Measures if the stock price of Navidea is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of -2.58 means the investor is paying $-2.58 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Navidea Biopharmaceuticals Inc:

  • The EOD is -0.001. Based on the equity, the company is expensive. -2
  • The MRQ is -2.581. Based on the equity, the company is expensive. -2
  • The TTM is -2.581. Based on the equity, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-0.001MRQ-2.581+2.580
MRQ-2.581TTM-2.5810.000
TTM-2.581YOY160.200-162.781
TTM-2.5815Y24.778-27.359
5Y24.77810Y6.544+18.234
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-0.0012.022-2.023
MRQ-2.5812.054-4.635
TTM-2.5812.386-4.967
YOY160.2002.442+157.758
5Y24.7783.696+21.082
10Y6.5444.311+2.233
4.6.2. Total Gains per Share

4.7 Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Navidea Biopharmaceuticals Inc.

3rd party ad coffee SUPPORTERis ad-free.

5. Financial Statements




5.1. Reversals in quarterly reports

I have detected a reversal (positive to negative, negative to positive) in the following values of the quarterly reports.

 2018-12-312019-12-312020-12-312021-12-312022-12-31
Gross Profit  226-20620894914-581333-452-119



5.2. Latest Balance Sheet

Balance Sheet of 2022-12-31. Currency in USD. All numbers in thousands.

Summary
Total Assets4,372
Total Liabilities12,515
Total Stockholder Equity-8,436
 As reported
Total Liabilities 12,515
Total Stockholder Equity+ -8,436
Total Assets = 4,372

Assets

Total Assets4,372
Total Current Assets3,204
Long-term Assets1,168
Total Current Assets
Cash And Cash Equivalents 1,996
Net Receivables 1
Inventory 427
Other Current Assets 780
Total Current Assets  (as reported)3,204
Total Current Assets  (calculated)3,204
+/-0
Long-term Assets
Property Plant Equipment 156
Intangible Assets 1,000
Other Assets 12
Long-term Assets  (as reported)1,168
Long-term Assets  (calculated)1,168
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities9,942
Long-term Liabilities2,573
Total Stockholder Equity-8,436
Total Current Liabilities
Short-term Debt 563
Short Long Term Debt 544
Accounts payable 2,123
Other Current Liabilities 6,457
Total Current Liabilities  (as reported)9,942
Total Current Liabilities  (calculated)9,686
+/- 256
Long-term Liabilities
Long term Debt 1,872
Capital Lease Obligations 20
Other Liabilities 701
Long-term Liabilities Other 1
Long-term Liabilities  (as reported)2,573
Long-term Liabilities  (calculated)2,595
+/- 22
Total Stockholder Equity
Common Stock224
Retained Earnings -388,003
Other Stockholders Equity 379,343
Total Stockholder Equity (as reported)-8,436
Total Stockholder Equity (calculated)-8,436
+/- 0
Other
Capital Stock224
Cash and Short Term Investments 1,996
Common Stock Shares Outstanding 30,902
Current Deferred Revenue800
Liabilities and Stockholders Equity 4,372
Net Debt 440
Net Invested Capital -6,021
Net Tangible Assets -9,436
Net Working Capital -6,738
Property Plant and Equipment Gross 943
Short Long Term Debt Total 2,436



5.3. Balance Sheets Structured

Currency in USD. All numbers in thousands.

 Trend2022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-312015-12-312014-12-312013-12-312012-12-312011-12-312010-12-312009-12-312008-12-312007-12-312006-12-312005-12-312004-12-312003-12-312002-12-312001-12-312000-12-311999-12-311998-12-311997-12-311996-12-311995-12-311994-12-311993-12-311992-12-31
> Total Assets 
13,000
12,600
24,100
24,100
63,873
41,573
11,994
10,323
7,573
11,329
7,080
7,385
15,366
11,570
8,034
7,063
9,619
9,018
10,863
31,194
11,972
40,317
11,920
14,965
12,462
20,781
7,009
4,151
7,758
6,645
4,372
4,3726,6457,7584,1517,00920,78112,46214,96511,92040,31711,97231,19410,8639,0189,6197,0638,03411,57015,3667,3857,08011,3297,57310,32311,99441,57363,87324,10024,10012,60013,000
   > Total Current Assets 
12,600
10,500
20,000
20,000
53,664
29,301
8,019
7,144
6,182
6,548
3,090
4,051
11,437
8,448
5,334
4,647
7,241
8,617
10,233
30,047
10,617
37,331
8,599
12,577
10,826
13,832
4,975
2,916
6,528
5,383
3,204
3,2045,3836,5282,9164,97513,83210,82612,5778,59937,33110,61730,04710,2338,6177,2414,6475,3348,44811,4374,0513,0906,5486,1827,1448,01929,30153,66420,00020,00010,50012,600
       Cash And Cash Equivalents 
8,600
1,300
10,000
10,000
30,168
9,921
3,055
4,883
4,643
4,287
701
1,589
9,843
4,941
2,503
1,540
3,566
5,640
6,421
28,644
9,119
32,939
5,479
7,166
1,539
4,593
3,476
1,047
2,670
4,231
1,996
1,9964,2312,6701,0473,4764,5931,5397,1665,47932,9399,11928,6446,4215,6403,5661,5402,5034,9419,8431,5897014,2874,6434,8833,0559,92130,16810,00010,0001,3008,600
       Short-term Investments 
0
0
0
0
19,749
14,672
449
0
0
0
0
0
0
1,529
0
0
495
0
0
0
0
0
0
0
5,001
1,798
799
0
0
0
0
00007991,7985,0010000000495001,52900000044914,67219,7490000
       Net Receivables 
0
8,100
1,400
200
1,240
2,293
2,070
453
365
561
746
1,108
412
673
1,246
1,622
1,644
1,332
2,048
16
18
1,151
817
3,703
1,802
8,138
21
901
2,987
93
1
1932,987901218,1381,8023,7038171,15118162,0481,3321,6441,6221,2466734121,1087465613654532,0702,2931,2402001,4008,1000
       Inventory 
200
700
500
500
216
413
1,579
1,134
941
1,431
1,192
1,008
855
804
1,154
1,237
962
1,144
1,459
822
298
2,232
932
653
1,471
0
0
-901
170
151
427
427151170-901001,4716539322,2322988221,4591,1449621,2371,1548048551,0081,1921,4319411,1341,579413216500500700200
       Other Current Assets 
3,800
400
8,100
9,300
684
790
147
674
2
268
452
346
327
502
431
247
574
2,977
306
565
1,499
4,392
3,120
5,411
6,014
1,102
678
967
701
908
780
7809087019676781,1026,0145,4113,1204,3921,4995653062,97757424743150232734645226826741477906849,3008,1004003,800
   > Long-term Assets 
400
2,100
4,100
4,100
10,210
12,272
3,975
3,178
1,391
4,781
3,990
3,334
3,929
3,122
2,700
2,416
2,379
401
630
1,147
1,355
2,985
3,321
2,387
1,635
6,949
2,035
1,235
1,230
1,262
1,168
1,1681,2621,2301,2352,0356,9491,6352,3873,3212,9851,3551,1476304012,3792,4162,7003,1223,9293,3343,9904,7811,3913,1783,97512,27210,2104,1004,1002,100400
       Property Plant Equipment 
200
1,700
3,600
3,600
6,448
10,425
1,419
903
865
669
463
363
338
283
356
288
391
297
520
463
935
2,125
2,510
1,928
1,252
237
162
312
382
249
156
1562493823121622371,2521,9282,5102,1259354635202973912883562833383634636698659031,41910,4256,4483,6003,6001,700200
       Long Term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
242
0
0
0
0
0
0
0
0
000000002420000000000000000000000
       Intangible Assets 
200
300
500
500
2,130
0
774
775
524
3,910
3,366
2,936
2,519
2,099
1,829
1,601
1,393
79
103
85
92
137
181
186
181
458
428
385
620
786
1,000
1,0007866203854284581811861811379285103791,3931,6011,8292,0992,5192,9363,3663,91052477577402,130500500300200
       Other Assets 
0
0
0
0
0
0
0
0
526
4,112
161
35
1,072
740
516
528
594
25
7
599
328
723
388
274
308
6,254
835
538
384
1,262
12
121,2623845388356,2543082743887233285997255945285167401,072351614,11252600000000
> Total Liabilities 
600
1,800
4,100
4,100
8,596
9,019
7,169
10,462
4,607
4,425
3,120
2,126
9,202
7,554
8,332
11,007
9,645
18,888
6,731
10,062
13,378
44,326
41,724
68,800
80,128
8,733
4,611
5,032
5,711
6,020
12,515
12,5156,0205,7115,0324,6118,73380,12868,80041,72444,32613,37810,0626,73118,8889,64511,0078,3327,5549,2022,1263,1204,4254,60710,4627,1699,0198,5964,1004,1001,800600
   > Total Current Liabilities 
600
1,600
2,900
2,900
7,587
6,950
7,013
6,147
2,374
2,476
1,950
1,541
1,010
1,502
3,409
2,171
2,322
2,403
3,944
3,348
6,191
11,291
9,095
6,184
69,862
8,068
3,379
3,820
4,715
5,300
9,942
9,9425,3004,7153,8203,3798,06869,8626,1849,09511,2916,1913,3483,9442,4032,3222,1713,4091,5021,0101,5411,9502,4762,3746,1477,0136,9507,5872,9002,9001,600600
       Short-term Debt 
100
200
400
400
231
359
1,342
3,222
117
175
187
202
257
220
1,848
139
147
11
62
6
2,757
4,096
4,383
333
51,958
2,354
316
807
1,335
1,005
563
5631,0051,3358073162,35451,9583334,3834,0962,757662111471391,8482202572021871751173,2221,342359231400400200100
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
4,349
333
51,958
2,354
316
306
745
453
544
5444537453063162,35451,9583334,3490000000000000000000000
       Accounts payable 
500
1,300
1,600
2,500
2,405
3,848
2,858
760
732
490
432
225
199
208
668
778
731
764
1,523
682
1,417
2,422
1,477
1,768
7,123
855
425
1,112
1,162
1,421
2,123
2,1231,4211,1621,1124258557,1231,7681,4772,4221,4176821,5237647317786682081992254324907327602,8583,8482,4052,5001,6001,300500
       Other Current Liabilities 
0
100
900
0
2,000
2,899
2,913
2,166
726
1,011
397
227
378
822
544
802
918
1,067
1,704
579
3,434
7,195
4,712
3,039
8,466
5,715
1,771
1,900
2,218
2,833
6,457
6,4572,8332,2181,9001,7715,7158,4663,0394,7127,1953,4345791,7041,0679188025448223782273971,0117262,1662,9132,8992,00009001000
   > Long-term Liabilities 
0
100
1,200
1,200
1,009
2,069
156
4,314
2,233
1,949
1,169
585
8,192
6,052
4,922
8,836
7,323
16,485
2,787
6,714
7,187
33,035
32,629
62,616
10,266
665
1,233
1,212
996
720
2,573
2,5737209961,2121,23366510,26662,61632,62933,0357,1876,7142,78716,4857,3238,8364,9226,0528,1925851,1691,9492,2334,3141562,0691,0091,2001,2001000
       Long term Debt Total 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
6,456
0
31,265
29,539
60,746
9,641
0
0
0
0
0
0
0000009,64160,74629,53931,26506,4560000000000000000000
       Other Liabilities 
0
0
0
0
0
0
0
0
2,200
1,929
1,165
106
2,670
46
44
3,530
1,389
2,519
2,787
252
249
9,457
3,087
1,870
625
665
1,233
700
700
700
701
7017007007001,2336656251,8703,0879,4572492522,7872,5191,3893,53044462,6701061,1651,9292,20000000000
       Deferred Long Term Liability 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
193
26
0
0
0
0
0
0
0000002619300000000000000000000000
> Total Stockholder Equity
12,400
10,900
20,000
20,000
55,277
32,554
4,826
-139
2,966
6,904
3,960
5,259
6,164
4,017
-298
-3,944
-26
-9,870
4,132
21,132
-1,405
-4,010
-29,803
-54,305
-68,135
11,380
1,730
-1,612
1,316
-107
-8,436
-8,436-1071,316-1,6121,73011,380-68,135-54,305-29,803-4,010-1,40521,1324,132-9,870-26-3,944-2984,0176,1645,2593,9606,9042,966-1394,82632,55455,27720,00020,00010,90012,400
   Common Stock
0
0
0
0
23
23
23
23
26
36
37
52
58
59
60
67
71
81
86
95
113
136
150
156
156
162
200
210
218
221
224
224221218210200162156156150136113958681716760595852373626232323230000
   Retained Earnings -388,003-370,788-359,057-347,671-336,723-319,909-394,855-380,547-352,984-317,257-274,558-245,357-250,870-192,699-148,840-140,777-135,688-130,947-126,018-122,477-120,678-117,714-117,729-119,569-115,395-87,363-64,116-43,100-43,100-21,800-13,900
   Capital Surplus 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
266,394
273,039
313,112
323,030
326,086
326,564
331,129
338,265
345,848
375,428
0
0
00375,428345,848338,265331,129326,564326,086323,030313,112273,039266,3940000000000000000000
   Treasury Stock0000000-53,83600000000000000000000000
   Other Stockholders Equity 
26,300
32,700
63,100
63,100
119,294
120,035
120,273
120,672
121,843
126,084
126,486
129,560
134,128
134,903
137,213
138,396
145,742
182,748
256,766
267,372
273,039
314,595
324,645
328,029
328,897
331,129
338,253
345,849
360,154
370,460
379,343
379,343370,460360,154345,849338,253331,129328,897328,029324,645314,595273,039267,372256,766182,748145,742138,396137,213134,903134,128129,560126,486126,084121,843120,672120,273120,035119,29463,10063,10032,70026,300



5.4. Balance Sheets

Currency in USD. All numbers in thousands.




5.5. Cash Flows

Currency in USD. All numbers in thousands.




5.6. Income Statements

Currency in USD. All numbers in thousands.


5.7. Latest Income Statement

Income Statement (annual), 2023-12-31. Currency in USD. All numbers in thousands.

Gross Profit (+$)
totalRevenue1
Cost of Revenue-50
Gross Profit-49-49
 
Operating Income (+$)
Gross Profit-49
Operating Expense-10,130
Operating Income-10,180-10,180
 
Operating Expense (+$)
Research Development5,093
Selling General Administrative5,037
Selling And Marketing Expenses-
Operating Expense10,13010,130
 
Net Interest Income (+$)
Interest Income-
Interest Expense--
Other Finance Cost-3
Net Interest Income3
 
Pretax Income (+$)
Operating Income-10,180
Net Interest Income3
Other Non-Operating Income Expenses-
Income Before Tax (EBT)-8,607-11,749
EBIT - interestExpense = -10,773
-9,203
-1,182
Interest Expense-
Earnings Before Interest and Taxes (EBIT)-10,773-8,607
Earnings Before Interest and Taxes (EBITDA)-10,664
 
After tax Income (+$)
Income Before Tax-8,607
Tax Provision--
Net Income From Continuing Ops-8,607-8,607
Net Income-1,182
Net Income Applicable To Common Shares-
 
Non-recurring Events
Discontinued Operations-
Extraordinary Items-
Effect of Accounting Charges-
Other Items-
Non Recurring-
Other Operating Expenses10,180
Total Other Income/Expenses Net1,569-3
 

Technical Analysis of Navidea
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Navidea. The general trend of Navidea is BEARISH with 100.0% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Navidea's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (-100.0%) Bearish trend (100.0%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Navidea Biopharmaceuticals Inc.

The long score for the Support & Resistance is 1/1.
The longshort score for the Support & Resistance is 1/(-1 +1).

  • Around support: The price is currently trading around a support level. This can be considered as a potential entry level. +1

The bullish price targets are: 0.0002 < 0.001 < 0.001.

The bearish price targets are: 0.0001 > 0.0001 > 0.0001.

Tweet this
Navidea Biopharmaceuticals Inc Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Navidea Biopharmaceuticals Inc. The current mas is .

The long score for the Moving Averages is 0/14.
The longshort score for the Moving Averages is -14/(-14 +14).

  • MA 20 trending down: The MA 20 is trending down. -1
  • Close < MA 20: The price is below the MA 20. -1
  • MA 20 < MA 50: The MA 20 is lower than the MA 50. -1
  • MA 20 < MA 100: The MA 20 is lower than the MA 100. -1
  • MA 20 < MA 200: The MA 20 is lower than the MA 200. -1
  • MA 50 trending down: The MA 50 is trending down. -1
  • Close < MA 50: The price is below the MA 50. -1
  • MA 50 < MA 100: The MA 50 is lower than the MA 100. -1
  • MA 50 < MA 200: The MA 50 is lower than the MA 200. -1
  • MA 100 trending down: The MA 100 is trending down. -1
  • Close < MA 100: The price is below the MA 100. -1
  • MA 100 < MA 200: The MA 100 is lower than the MA 200. -1
  • MA 200 trending down: The MA 200 is trending down. -1
  • Close < MA 200: The price is below the MA 200. -1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Navidea Biopharmaceuticals Inc Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Navidea Biopharmaceuticals Inc. The current macd is -0.00022624.

The long score for the Moving Average Convergence/Divergence (MACD) is 0/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is -4/(-4 +4).

  • MACD line < signal line: The MACD line is below the signal line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Navidea price going down in the near term. -2
  • MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for Navidea. This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the Navidea price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
  • Trending down: The MACD line is trending down. This indicates that the short-term moving average is falling faster than the long-term moving average, suggesting negative momentum in the market. This signals that sellers are becoming more active and insecure, leading to potential price decreases as traders anticipate further losses and are willing to sell at lower prices. -1
Navidea Biopharmaceuticals Inc Daily Moving Average Convergence/Divergence (MACD) ChartNavidea Biopharmaceuticals Inc Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Navidea Biopharmaceuticals Inc. The current adx is 83.59.

The long score for the Directional Movement Index (DMI) is 3/7.
The longshort score for the Directional Movement Index (DMI) is 3/(-7 +7).

  • PLUS_ID > MINUS_DI: The +DI line is above the -DI line. This indicates a bullish signal in the market, as the positive directional movement is currently stronger than the negative directional movement, showing that buyers have the upper hand. Market psychology suggests that traders are optimistic, expecting further price increases, and are more willing to buy Navidea shares, leading to potential upward momentum in its price. +1
  • PLUS_ID > MINUS_DI && ADX > 25 && ADX trending down: The ADX is above 25 and indicates a strong bullish trend. The ADX is declining, the bullish trend is weakening. Could be a potential reversal to the downside. +2
Navidea Biopharmaceuticals Inc Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Navidea Biopharmaceuticals Inc. The current sar is 0.01423994.

The long score for the Parabolic SAR is 0/1.
The longshort score for the Parabolic SAR is -1/(-1 +1).

  • Close < SAR: The price is below the SAR. It's generally considered a bearish signal. -1
Navidea Biopharmaceuticals Inc Daily Parabolic SAR Chart
3rd party ad coffee SUPPORTERis ad-free.

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Navidea Biopharmaceuticals Inc. The current rsi is 27.88. The current phase is Oversold in bear market.

The long score for the Relative Strength Index (RSI) is 1/13.
The longshort score for the Relative Strength Index (RSI) is 1/(-13 +13).

  • Oversold in bear market: Short-term excessive selling, potential for relief rally. Be cautious, consider taking short-term long positions. +1
Navidea Biopharmaceuticals Inc Daily Relative Strength Index (RSI) ChartNavidea Biopharmaceuticals Inc Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Navidea Biopharmaceuticals Inc. The current phase is Oversold in bear market.

The long score for the Stochastic Oscillator is 0/6.
The longshort score for the Stochastic Oscillator is -6/(-6 +6).

  • STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
  • STOCH < 20: The STOCH %K is below 20 and oversold. -2
  • STOCH %K line < STOCH %D line: The STOCH %K line is below the STOCH %D line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Navidea price going down in the near term. -2
  • Trending down: The STOCH %K is trending down. -1
Navidea Biopharmaceuticals Inc Daily Stochastic Oscillator ChartNavidea Biopharmaceuticals Inc Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Navidea Biopharmaceuticals Inc. The current cci is -78.65892972.

Navidea Biopharmaceuticals Inc Daily Commodity Channel Index (CCI) ChartNavidea Biopharmaceuticals Inc Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Navidea Biopharmaceuticals Inc. The current cmo is -49.29644161.

The long score for the Chande Momentum Oscillator (CMO) is 0/1.
The longshort score for the Chande Momentum Oscillator (CMO) is -1/(-1 +1).

  • CMO < 0: The CMO is below 0, the momentum of the price is negative, indicating a potential downtrend in the price. -1
Navidea Biopharmaceuticals Inc Daily Chande Momentum Oscillator (CMO) ChartNavidea Biopharmaceuticals Inc Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Navidea Biopharmaceuticals Inc. The current willr is -100.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is -1/(-1 +1).

  • WILLR < -80: The Williams %R is below -80. This indicates that the price is in oversold territory, suggesting a potential price correction or trend reversal to the upside. -1
Navidea Biopharmaceuticals Inc Daily Williams %R ChartNavidea Biopharmaceuticals Inc Daily Williams %R Chart
3rd party ad coffee SUPPORTERis ad-free.

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Navidea Biopharmaceuticals Inc.

Navidea Biopharmaceuticals Inc Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Navidea Biopharmaceuticals Inc. The current atr is 0.00034042.

Navidea Biopharmaceuticals Inc Daily Average True Range (ATR) ChartNavidea Biopharmaceuticals Inc Daily Average True Range (ATR) Chart
3rd party ad coffee SUPPORTERis ad-free.

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Navidea Biopharmaceuticals Inc. The current obv is 229,864,843.

Navidea Biopharmaceuticals Inc Daily On-Balance Volume (OBV) ChartNavidea Biopharmaceuticals Inc Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Navidea Biopharmaceuticals Inc. The current mfi is 97.73.

The long score for the Money Flow Index (MFI) is 2/2.
The longshort score for the Money Flow Index (MFI) is 2/(-2 +2).

  • MFI > 50: +1
  • MFI > 80: +1
Navidea Biopharmaceuticals Inc Daily Money Flow Index (MFI) ChartNavidea Biopharmaceuticals Inc Daily Money Flow Index (MFI) Chart
3rd party ad coffee SUPPORTERis ad-free.

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Navidea Biopharmaceuticals Inc.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2024-08-02WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-08-14CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-08-15STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-09-03WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-09-17SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-09-19SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-09-30CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-10-18WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-11-04MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-11-06RSI LONG ENTRY SHORT CLOSE30 crossover to upside
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-11-08CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-11-11MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2024-11-12STOCH LONG EXITThe %K line crosses below the %D line.
2024-11-22MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-11-29MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-12-03MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-12-05RSI LONG ENTRY SHORT CLOSE30 crossover to upside
2024-12-06STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside

6.3. Candlestick Patterns

Navidea Biopharmaceuticals Inc Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Navidea Biopharmaceuticals Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5027.880
Ma 20Greater thanMa 500.001
Ma 50Greater thanMa 1000.001
Ma 100Greater thanMa 2000.001
OpenGreater thanClose0.000
Total0/5 (0.0%)
Penke
Good job! You gained 25 XP and 0   0   10 . What's next:
  • Share my analysis of Navidea with someone you think should read this too:
  • Are you bullish or bearish on Navidea? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Navidea? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Navidea Biopharmaceuticals Inc

I send you an email if I find something interesting about Navidea Biopharmaceuticals Inc.


Comments

How you think about this?

Leave a comment

Stay informed about Navidea Biopharmaceuticals Inc.

Receive notifications about Navidea Biopharmaceuticals Inc in your mailbox!

3rd party ad coffee SUPPORTERis ad-free.